Locations:
Search
Blinatumomab plus chemotherapy improves overall survival and relapse-free survival over chemotherapy alone
Real-world study shows high response rates that are durable with commercial lisocabtagene maraleucel
First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention
Global R&D efforts expanding first-line and relapse therapy options for patients
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A case study on the value of access to novel therapies through clinical trials
Two thirds of patients responded to CAR T-cell therapy
On-demand stem cell mobilizer is an effective salvage strategy
Dispelling myths and sharing practical experiences
Research indicates strong rationale for expanding trial eligibility criteria
Retrospective study yields clues to understanding risk of secondary myeloid neoplasms
Advertisement
Advertisement